10/24/2026
🧬 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐔𝐩𝐝𝐚𝐭𝐞𝐬 𝐢𝐧 𝐌𝐄𝐅𝟐𝐂 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡!
Want to hear the latest information on MEF2C gene therapy progress? Join us on 𝐒𝐮𝐧𝐝𝐚𝐲, 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟖𝐭𝐡 𝐚𝐭 𝟒 𝐏𝐌 𝐄𝐓/ 𝟑 𝐏𝐌 𝐂𝐓 for a webinar featuring top experts in the field.
🔹𝐃𝐫. 𝐒𝐭𝐞𝐯𝐞𝐧 𝐆𝐫𝐚𝐲 (𝐔𝐓𝐒𝐖) will share updates on his lab's preclinical MEF2C gene therapy research and explain the science behind AAV9, and the novel capsid CapX.
🔹𝐃𝐫. 𝐁𝐫𝐚𝐧𝐝𝐨𝐧 𝐇𝐞𝐧𝐫𝐲 (𝐀𝐮𝐫𝐞𝐥𝐢𝐱 𝐁𝐢𝐨) will break down the regulatory pathway forward and how rare disease therapies progress from benchside to bedside.
🗓️ 𝐃𝐚𝐭𝐞:Sunday, November 8, 2026
⏰ 𝐓𝐢𝐦𝐞: 4 PM ET / 3 PM CT
📍 Save your spot: https://forms.gle/rQJnVWouEpdbvpdPA
Steven Gray, Ph.D., is a Professor in the Department of Pediatrics at UT Southwestern Medical Center, co-director of the UTSW Gene Therapy Program, and director of the UTSW Viral Vector Facility. He holds a Ph.D. in molecular biology from Vanderbilt University and completed postdoctoral training at the UNC Chapel Hill Gene Therapy Center. A leader in AAV vector engineering and viral vector manufacturing, Dr. Gray’s research focuses on developing adeno-associated virus (AAV) gene therapies for rare, severe central nervous system disorders and facilitating their translation from benchside to Phase I clinical trials.
Brandon M. Henry, M.D., FACSc, is a physician-scientist serving as the Chief Executive and Medical Officer at Aurelix Bio, as well as Chief Medical Officer for the FOXG1 Research Foundation. He specializes in the clinical and regulatory development of gene replacement therapies for rare genetic diseases. His work centers on translating complex, gene-directed science into patient-centered clinical programs and navigating regulatory pathways to advance therapies safely from preclinical models to human trials.
